BRANMOOR
THURSDAY · 14 MAY 2026

Methotrexate

Injection

Current Active — Day 1158 FDA record updated

High impact — Only one manufacturer supplies this drug; any disruption leaves no immediate alternative source.

FDA shortage record

Substance
Methotrexate
Manufacturers / suppliers
  • Hikma Pharmaceuticals USA Inc.
  • Hikma Pharmaceuticals USA, Inc.
2 known suppliers in current FDA data
Dosage form
Injection
Presentation
Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)
Route(s)
INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS
Therapeutic category
Rheumatology, Oncology
Package NDC
0143-9830-01
Initially posted
03/13/2023
Days on shortage list
1158
Current FDA status
Current
Shortage entries (current dataset)
1 record for Methotrexate

Why this shortage matters

Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.

FDA therapeutic class: Rheumatology, Oncology

Reason and context

Additional product will be made available as it is released.

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.

If you're affected by this shortage

  • Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
  • Ask your pharmacy to check supply across multiple wholesalers and other branches.
  • Check current pharmacy pricing and availability via GoodRx (affiliate link).
  • Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.